SCHEMBL2432871

SCHEMBL2432871

CCOC(=O)Cc1ccc2nc(Nc3ccccc3Br)oc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.51
RAB9A P51151 5/20 0.51
MAPT P10636 2/20 0.50
ITGA4 P13612 8/20 0.46
ITGB1 P05556 2/20 0.46
C1R P00736 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
PKM P14618 3/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 1/20 0.42
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41
TP53 P04637 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GALK1 P51570 1/20 0.40
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2432781 0.85 C1R (0.51) NPC1RAB9AITGA4ITGB1C1R
SCHEMBL14591722 0.83 NPC1 (0.50) NPC1RAB9AITGA4ITGB1C1R
SCHEMBL2435619 0.81 ITGA4 (0.53) NPC1RAB9AMAPTITGA4ITGB1
SCHEMBL5160127 0.80 MAPT (0.60) NPC1RAB9AMAPTITGA4ITGB1
SCHEMBL5270908 0.80 NPC1 (0.49) NPC1RAB9AMAPTITGA4ITGB1
SCHEMBL2434527 0.78 NPC1 (0.55) NPC1RAB9AMAPTITGA4ITGB1
SCHEMBL27596503 0.78 NPC1 (0.51) NPC1RAB9AMAPTITGA4C1R
SCHEMBL24894178 0.77 NPC1 (0.61) NPC1RAB9AMAPTC1RSMN1; SMN2
SCHEMBL30194619 0.77 NPC1 (0.61) NPC1RAB9AMAPTC1RSMN1; SMN2
SCHEMBL27596597 0.76 MAPT (0.46) NPC1RAB9AMAPTITGA4ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
CN-100471838-C VLA-4 inhibitors DAIICHI SEIYAKU CO (JP) 2009-03-25 CN disclosed
CN-100396680-C Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2008-06-25 CN disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
CN-1699363-A Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2005-11-23 CN disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
CN-1483024-A Vla-4 inhibitors ��һ��������ҩ��ʽ���� 2004-03-17 CN disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 NPC1 1278/4885RAB9A 2530/4885MAPT 4631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.